- Home
- FOR vs ATAI Comparison
FOR vs ATAI Comparison
Compare FOR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOR | ATAI |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FOR | ATAI |
|---|---|---|
| Price | $28.06 | $4.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $32.67 | $15.88 |
| AVG Volume (30 Days) | 121.4K | ★ 6.3M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $1,662,400,000.00 | $4,089,000.00 |
| Revenue This Year | $0.34 | N/A |
| Revenue Next Year | $7.73 | N/A |
| P/E Ratio | $92.20 | ★ N/A |
| Revenue Growth | 10.14 | ★ 1227.60 |
| 52 Week Low | $18.50 | $1.29 |
| 52 Week High | $30.74 | $6.73 |
Technical Indicators
Market Signals| Indicator | FOR | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 62.74 |
| Support Level | $24.04 | $3.41 |
| Resistance Level | $29.17 | $4.68 |
| Average True Range (ATR) | 0.91 | 0.31 |
| MACD | 0.31 | 0.10 |
| Stochastic Oscillator | 91.52 | 51.93 |
Price Performance
Historical ComparisonAbout FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.